Fractyl Health Inc (GUTS)
Fractyl Health, Inc. is a healthcare company focused on metabolic therapeutics for type 2 diabetes and obesity. Its development programs include Revita DMR System, an outpatient procedure intended to address duodenal dysfunction associated with high-fat and high-sugar diets, and Rejuva, an adeno-associated virus delivered pancreatic gene therapy platform designed to support longer-term remission of these conditions by targeting metabolic hormone function in pancreatic islet cells. The company, which was incorporated in 2010, changed its name from Fractyl Laboratories Inc. to Fractyl Health, Inc. in June 2021. Fractyl Health is headquartered in Burlington, Massachusetts, and its common stock trades on NASDAQ under the symbol GUTS.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GUTS
|
$0.86
|
13.5% Upside
|
Fair
|
$5.03
|
562.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-1.1x
|
5.6x
|
—
|
123.9 M
|
118.2 M
|
33.0%
|
90.3%
|
-9.2
|
—
|
81.3%
|
